Monopar Therapeutics Inc. Prepaid Expense and Other Assets
Monopar Therapeutics Inc. (MNPR) had Prepaid Expense and Other Assets of $114.57 thousand as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Balance Sheet › Assets
us-gaap:PrepaidExpenseAndOtherAssets · last filed 2021-05-13
- 2021-03-31: Prepaid Expense and Other Assets $114.57K.
- 2020-12-31: Prepaid Expense and Other Assets $62.69K.
- 2020-09-30: Prepaid Expense and Other Assets $104.55K.
- 2020-06-30: Prepaid Expense and Other Assets $183.42K.
| Period end | Prepaid Expense and Other Assets | Prepaid Expense and Other Assets as first filed |
|---|---|---|
| 2021-03-31 | $114.57K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $62.69K 10-Q · filed 2021-05-13 | |
| 2020-09-30 | $104.55K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $183.42K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $124.19K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $15.71K 10-Q · filed 2020-11-12 | $5.38K 10-K · filed 2020-03-27 |
| 2019-09-30 | $84.88K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $94.15K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $101.63K 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $14.52K 10-K · filed 2020-03-27 | $425.18K 10-K · filed 2019-02-26 |
| 2018-09-30 | $269.51K 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $228.05K 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $175.10K 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $149.34K 10-K · filed 2019-02-26 | |
| 2016-12-31 | $22.56K 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |